Impax announced that the Food and Drug Administration (FDA) has approved Glyburide Tablets, the generic version of Sanofi AventisDiabeta.

Diabeta is a second-generation sulfonylurea indicated as adjunct to diet and exercises in type 2 diabetes mellitus. The mechanism of action is unknown but it appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets.

RELATED: Glyburide Use in Moms May Up Neonatal Adverse Events

Glyburide Tablets will be available in 1.25mg, 2.5mg, and 5mg strengths.

For more information call (215) 558-4300 or visit